Loading...

Jeremy Rich

TitleClinical Professor
InstitutionUniversity of California San Diego
DepartmentMedicine
Address9500 Gilman Drive #0695
La Jolla CA 92093
Phone858-822-2703
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    Duke University School of Medicine, Durham, NCMHS05/2009Clinical Research Training Program
    Baldwin Wallace University, Parma, OHMBA05/2016Health Care
    Duke University Medical Center, Durham, NC06/1998Neuro-Oncology
    Johns Hopkins Hospital, Baltimore, MD06/1997Neurology
    Johns Hopkins Hospital, Baltimore, MD06/1994Internal Medicine
    Duke University School of Medicine, Durham, NCMD05/1993Medicine
    Washington University, St. Louis, MOB.S.05/1989Electrical Engineering

    Collapse Research 
    Collapse Research Activities and Funding
    Dual Targeting of Brain Tumor Initiating Cells through Inhibition of BMI1 and EZH2
    NIH/NINDS R01NS103434Sep 30, 2017 - Jun 30, 2022
    Role: Principal Investigator
    Dynamic Complexity of Brain Tumor Stem Cells
    NIH/NCI R35CA197718Aug 1, 2015 - Aug 31, 2022
    Role: Principal Investigator
    Instructive Cues in Glioblastoma Hierarchies
    NIH/NCI R01CA171652Aug 15, 2014 - Jul 31, 2019
    Role: Principal Investigator
    Energy Stress in Brain Tumor Initiating Stem Cells
    NIH/NINDS R01NS089272Aug 1, 2014 - Jul 31, 2019
    Role: Principal Investigator
    Metabolism Informs Intertumoral & Intratumoral Heterogeneity
    NIH/NINDS R01NS087913Apr 15, 2014 - Feb 28, 2019
    Role: Co-Principal Investigator
    Targeting Ferritin in Glioblastoma
    NIH/NCI R01CA169117Jul 1, 2013 - Apr 30, 2018
    Role: Co-Principal Investigator
    Targeting Brain Tumor Stem Cells Through Novel Therapeutic Combinations
    NIH/NCI R01CA154130Jul 1, 2010 - Dec 31, 2014
    Role: Principal Investigator
    Stem Cell-Like Glioma Cells in Angiogenesis
    NIH/NCI R01CA129958Apr 7, 2008 - Dec 31, 2013
    Role: Principal Investigator
    TGFbeta-PTEN Interactions in Glioma Biology &Therapy
    NIH/NCI R01CA116659Aug 1, 2006 - Dec 31, 2011
    Role: Principal Investigator
    Molecular Mechanisms of SPARC Mediated Glioma Invasion
    NIH/NINDS R01NS054276Feb 15, 2006 - Jan 31, 2011
    Role: Principal Investigator
    The Roles of Osteonectin and Osteoactivin in Gliomas
    NIH/NINDS K02NS047409Jun 1, 2004 - Feb 28, 2009
    Role: Principal Investigator
    TGF beta and Brain Tumors
    NIH/NINDS K08NS002055Jul 1, 1998 - Jun 30, 2003
    Role: Principal Investigator

    Collapse ORNG Applications 
    Collapse Featured Publications
    Collapse Websites

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Pei S, Minhajuddin M, Adane B, Khan N, Stevens BM, Mack SC, Lai S, Rich JN, Inguva A, Shannon KM, Kim H, Tan AC, Myers JR, Ashton JM, Neff T, Pollyea DA, Smith CA, Jordan CT. AMPK/FIS1-Mediated Mitophagy Is Required for Self-Renewal of Human AML Stem Cells. Cell Stem Cell. 2018 Jun 06. PMID: 29910151.
      View in: PubMed
    2. Shi Y, Guryanova OA, Zhou W, Liu C, Huang Z, Fang X, Wang X, Chen C, Wu Q, He Z, Wang W, Zhang W, Jiang T, Liu Q, Chen Y, Wang W, Wu J, Kim L, Gimple RC, Feng H, Kung HF, Yu JS, Rich JN, Ping YF, Bian XW, Bao S. Ibrutinib inactivates BMX-STAT3 in glioma stem cells to impair malignant growth and radioresistance. Sci Transl Med. 2018 May 30; 10(443). PMID: 29848664.
      View in: PubMed
    3. Wang X, Prager BC, Wu Q, Kim LJY, Gimple RC, Shi Y, Yang K, Morton AR, Zhou W, Zhu Z, Obara EAA, Miller TE, Song A, Lai S, Hubert CG, Jin X, Huang Z, Fang X, Dixit D, Tao W, Zhai K, Chen C, Dong Z, Zhang G, Dombrowski SM, Hamerlik P, Mack SC, Bao S, Rich JN. Reciprocal Signaling between Glioblastoma Stem Cells and Differentiated Tumor Cells Promotes Malignant Progression. Cell Stem Cell. 2018 Apr 05; 22(4):514-528.e5. PMID: 29625067.
      View in: PubMed
    4. Muretta JM, Reddy BJN, Scarabelli G, Thompson AF, Jariwala S, Major J, Venere M, Rich JN, Willard B, Thomas DD, Stumpff J, Grant BJ, Gross SP, Rosenfeld SS. A posttranslational modification of the mitotic kinesin Eg5 that enhances its mechanochemical coupling and alters its mitotic function. Proc Natl Acad Sci U S A. 2018 02 20; 115(8):E1779-E1788. PMID: 29432173.
      View in: PubMed
    5. Mack SC, Pajtler KW, Chavez L, Okonechnikov K, Bertrand KC, Wang X, Erkek S, Federation A, Song A, Lee C, Wang X, McDonald L, Morrow JJ, Saiakhova A, Sin-Chan P, Wu Q, Michaelraj KA, Miller TE, Hubert CG, Ryzhova M, Garzia L, Donovan L, Dombrowski S, Factor DC, Luu B, Valentim CLL, Gimple RC, Morton A, Kim L, Prager BC, Lee JJY, Wu X, Zuccaro J, Thompson Y, Holgado BL, Reimand J, Ke SQ, Tropper A, Lai S, Vijayarajah S, Doan S, Mahadev V, Miñan AF, Gröbner SN, Lienhard M, Zapatka M, Huang Z, Aldape KD, Carcaboso AM, Houghton PJ, Keir ST, Milde T, Witt H, Li Y, Li CJ, Bian XW, Jones DTW, Scott I, Singh SK, Huang A, Dirks PB, Bouffet E, Bradner JE, Ramaswamy V, Jabado N, Rutka JT, Northcott PA, Lupien M, Lichter P, Korshunov A, Scacheri PC, Pfister SM, Kool M, Taylor MD, Rich JN. Therapeutic targeting of ependymoma as informed by oncogenic enhancer profiling. Nature. 2018 01 04; 553(7686):101-105. PMID: 29258295.
      View in: PubMed
    6. Jin X, Jin X, Kim LJY, Dixit D, Jeon HY, Kim EJ, Kim JK, Lee SY, Yin J, Rich JN, Kim H. Inhibition of ID1-BMPR2 Intrinsic Signaling Sensitizes Glioma Stem Cells to Differentiation Therapy. Clin Cancer Res. 2018 Jan 15; 24(2):383-394. PMID: 29208670.
      View in: PubMed
    7. Sewastianik T, Jiang M, Sukhdeo K, Patel SS, Roberts K, Kang Y, Alduaij A, Dennis PS, Lawney B, Liu R, Song Z, Xiong J, Zhang Y, Lemieux ME, Pinkus GS, Rich JN, Weinstock DM, Mullighan CG, Sharpless NE, Carrasco RD. Constitutive Ras signaling and Ink4a/Arf inactivation cooperate during the development of B-ALL in mice. Blood Adv. 2017 Nov 28; 1(25):2361-2374. PMID: 29296886.
      View in: PubMed
    8. Zhou W, Chen C, Shi Y, Wu Q, Gimple RC, Fang X, Huang Z, Zhai K, Ke SQ, Ping YF, Feng H, Rich JN, Yu JS, Bao S, Bian XW. Targeting Glioma Stem Cell-Derived Pericytes Disrupts the Blood-Tumor Barrier and Improves Chemotherapeutic Efficacy. Cell Stem Cell. 2017 Nov 02; 21(5):591-603.e4. PMID: 29100012.
      View in: PubMed
    9. Bhasin S, Gill TM, Reuben DB, Latham NK, Gurwitz JH, Dykes P, McMahon S, Storer TW, Duncan PW, Ganz DA, Basaria S, Miller ME, Travison TG, Greene EJ, Dziura J, Esserman D, Allore H, Carnie MB, Fagan M, Hanson C, Baker D, Greenspan SL, Alexander N, Ko F, Siu AL, Volpi E, Wu AW, Rich J, Waring SC, Wallace R, Casteel C, Magaziner J, Charpentier P, Lu C, Araujo K, Rajeevan H, Margolis S, Eder R, McGloin JM, Skokos E, Wiggins J, Garber L, Clauser SB, Correa-De-Araujo R, Peduzzi P. Strategies to Reduce Injuries and Develop Confidence in Elders (STRIDE): A Cluster-Randomized Pragmatic Trial of a Multifactorial Fall Injury Prevention Strategy: Design and Methods. J Gerontol A Biol Sci Med Sci. 2017 Oct 14. PMID: 29045582.
      View in: PubMed
    10. Jin X, Kim LJY, Wu Q, Wallace LC, Prager BC, Sanvoranart T, Gimple RC, Wang X, Mack SC, Miller TE, Huang P, Valentim CL, Zhou QG, Barnholtz-Sloan JS, Bao S, Sloan AE, Rich JN. Targeting glioma stem cells through combined BMI1 and EZH2 inhibition. Nat Med. 2017 Nov; 23(11):1352-1361. PMID: 29035367.
      View in: PubMed
    11. Dashzeveg NK, Taftaf R, Ramos EK, Torre-Healy L, Chumakova A, Silver DJ, Alban TJ, Sinyuk M, Thiagarajan PS, Jarrar AM, Turaga SM, Saygin C, Mulkearns-Hubert E, Hitomi M, Rich JN, Gerson SL, Lathia JD, Liu H. New Advances and Challenges of Targeting Cancer Stem Cells. Cancer Res. 2017 10 01; 77(19):5222-5227. PMID: 28928129.
      View in: PubMed
    12. Zhu Z, Gorman MJ, McKenzie LD, Chai JN, Hubert CG, Prager BC, Fernandez E, Richner JM, Zhang R, Shan C, Tycksen E, Wang X, Shi PY, Diamond MS, Rich JN, Chheda MG. Correction: Zika virus has oncolytic activity against glioblastoma stem cells. J Exp Med. 2017 Oct 02; 214(10):3145. PMID: 28916645.
      View in: PubMed
    13. Zhu Z, Gorman MJ, McKenzie LD, Chai JN, Hubert CG, Prager BC, Fernandez E, Richner JM, Zhang R, Shan C, Tycksen E, Wang X, Shi PY, Diamond MS, Rich JN, Chheda MG. Zika virus has oncolytic activity against glioblastoma stem cells. J Exp Med. 2017 Oct 02; 214(10):2843-2857. PMID: 28874392.
      View in: PubMed
    14. Rosager AM, Sørensen MD, Dahlrot RH, Hansen S, Schonberg DL, Rich JN, Lathia JD, Kristensen BW. Transferrin receptor-1 and ferritin heavy and light chains in astrocytic brain tumors: Expression and prognostic value. PLoS One. 2017; 12(8):e0182954. PMID: 28837569.
      View in: PubMed
    15. Wang X, Huang Z, Wu Q, Prager BC, Mack SC, Yang K, Kim LJY, Gimple RC, Shi Y, Lai S, Xie Q, Miller TE, Hubert CG, Song A, Dong Z, Zhou W, Fang X, Zhu Z, Mahadev V, Bao S, Rich JN. MYC-Regulated Mevalonate Metabolism Maintains Brain Tumor-Initiating Cells. Cancer Res. 2017 09 15; 77(18):4947-4960. PMID: 28729418.
      View in: PubMed
    16. Miller TE, Liau BB, Wallace LC, Morton AR, Xie Q, Dixit D, Factor DC, Kim LJY, Morrow JJ, Wu Q, Mack SC, Hubert CG, Gillespie SM, Flavahan WA, Hoffmann T, Thummalapalli R, Hemann MT, Paddison PJ, Horbinski CM, Zuber J, Scacheri PC, Bernstein BE, Tesar PJ, Rich JN. Transcription elongation factors represent in vivo cancer dependencies in glioblastoma. Nature. 2017 07 20; 547(7663):355-359. PMID: 28678782.
      View in: PubMed
    17. Shi Y, Ping YF, Zhou W, He ZC, Chen C, Bian BS, Zhang L, Chen L, Lan X, Zhang XC, Zhou K, Liu Q, Long H, Fu TW, Zhang XN, Cao MF, Huang Z, Fang X, Wang X, Feng H, Yao XH, Yu SC, Cui YH, Zhang X, Rich JN, Bao S, Bian XW. Tumour-associated macrophages secrete pleiotrophin to promote PTPRZ1 signalling in glioblastoma stem cells for tumour growth. Nat Commun. 2017 Jun 01; 8:15080. PMID: 28569747.
      View in: PubMed
    18. Jung J, Kim LJY, Wang X, Wu Q, Sanvoranart T, Hubert CG, Prager BC, Wallace LC, Jin X, Mack SC, Rich JN. Nicotinamide metabolism regulates glioblastoma stem cell maintenance. JCI Insight. 2017 May 18; 2(10). PMID: 28515364.
      View in: PubMed
    19. Soeda A, Lathia J, Williams BJ, Wu Q, Gallagher J, Androutsellis-Theotokis A, Giles AJ, Yang C, Zhuang Z, Gilbert MR, Rich JN, Park DM. The p38 signaling pathway mediates quiescence of glioma stem cells by regulating epidermal growth factor receptor trafficking. Oncotarget. 2017 May 16; 8(20):33316-33328. PMID: 28410196.
      View in: PubMed
    20. Dixit D, Xie Q, Rich JN, Zhao JC. Messenger RNA Methylation Regulates Glioblastoma Tumorigenesis. Cancer Cell. 2017 04 10; 31(4):474-475. PMID: 28399407.
      View in: PubMed
    21. Ayuso JM, Monge R, Martínez-González A, Virumbrales-Muñoz M, Llamazares GA, Berganzo J, Hernández-Laín A, Santolaria J, Doblaré M, Hubert C, Rich JN, Sánchez-Gómez P, Pérez-García VM, Ochoa I, Fernández LJ. Glioblastoma on a microfluidic chip: Generating pseudopalisades and enhancing aggressiveness through blood vessel obstruction events. Neuro Oncol. 2017 04 01; 19(4):503-513. PMID: 28062831.
      View in: PubMed
    22. Wang X, Yang K, Xie Q, Wu Q, Mack SC, Shi Y, Kim LJY, Prager BC, Flavahan WA, Liu X, Singer M, Hubert CG, Miller TE, Zhou W, Huang Z, Fang X, Regev A, Suvà ML, Hwang TH, Locasale JW, Bao S, Rich JN. Purine synthesis promotes maintenance of brain tumor initiating cells in glioma. Nat Neurosci. 2017 May; 20(5):661-673. PMID: 28346452.
      View in: PubMed
    23. Shortell SM, Poon BY, Ramsay PP, Rodriguez HP, Ivey SL, Huber T, Rich J, Summerfelt T. A Multilevel Analysis of Patient Engagement and Patient-Reported Outcomes in Primary Care Practices of Accountable Care Organizations. J Gen Intern Med. 2017 Jun; 32(6):640-647. PMID: 28160187.
      View in: PubMed
    24. Liau BB, Sievers C, Donohue LK, Gillespie SM, Flavahan WA, Miller TE, Venteicher AS, Hebert CH, Carey CD, Rodig SJ, Shareef SJ, Najm FJ, van Galen P, Wakimoto H, Cahill DP, Rich JN, Aster JC, Suvà ML, Patel AP, Bernstein BE. Adaptive Chromatin Remodeling Drives Glioblastoma Stem Cell Plasticity and Drug Tolerance. Cell Stem Cell. 2017 02 02; 20(2):233-246.e7. PMID: 27989769.
      View in: PubMed
    25. Fang X, Zhou W, Wu Q, Huang Z, Shi Y, Yang K, Chen C, Xie Q, Mack SC, Wang X, Carcaboso AM, Sloan AE, Ouyang G, McLendon RE, Bian XW, Rich JN, Bao S. Deubiquitinase USP13 maintains glioblastoma stem cells by antagonizing FBXL14-mediated Myc ubiquitination. J Exp Med. 2017 Jan; 214(1):245-267. PMID: 27923907.
      View in: PubMed
    26. Shi Y, Zhou W, Cheng L, Chen C, Huang Z, Fang X, Wu Q, He Z, Xu S, Lathia JD, Ping Y, Rich JN, Bian XW, Bao S. Tetraspanin CD9 stabilizes gp130 by preventing its ubiquitin-dependent lysosomal degradation to promote STAT3 activation in glioma stem cells. Cell Death Differ. 2017 01; 24(1):167-180. PMID: 27740621.
      View in: PubMed
    27. Rich JN. Cancer stem cells: master gatekeepers and regulators of cancer growth and metastasis Introduction. Medicine (Baltimore). 2016 Sep; 95(1 Suppl 1):S1. PMID: 27611933.
      View in: PubMed
    28. Rich JN, Matsui WH, Chang JC. Cancer stem cells: A nuanced perspective. Medicine (Baltimore). 2016 Sep; 95(1 Suppl 1):S26-8. PMID: 27611936.
      View in: PubMed
    29. Rich JN. Cancer stem cells: understanding tumor hierarchy and heterogeneity. Medicine (Baltimore). 2016 Sep; 95(1 Suppl 1):S2-7. PMID: 27611934.
      View in: PubMed
    30. Jin X, Jeon HM, Jin X, Kim EJ, Yin J, Jeon HY, Sohn YW, Oh SY, Kim JK, Kim SH, Jung JE, Kwak S, Tang KF, Xu Y, Rich JN, Kim H. The ID1-CULLIN3 Axis Regulates Intracellular SHH and WNT Signaling in Glioblastoma Stem Cells. Cell Rep. 2016 08 09; 16(6):1629-1641. PMID: 27477274.
      View in: PubMed
    31. Burgett ME, Lathia JD, Roth P, Nowacki AS, Galileo DS, Pugacheva E, Huang P, Vasanji A, Li M, Byzova T, Mikkelsen T, Bao S, Rich JN, Weller M, Gladson CL. Direct contact with perivascular tumor cells enhances integrin avß3 signaling and migration of endothelial cells. Oncotarget. 2016 Jul 12; 7(28):43852-43867. PMID: 27270311.
      View in: PubMed
    32. Xie Q, Wu Q, Kim L, Miller TE, Liau BB, Mack SC, Yang K, Factor DC, Fang X, Huang Z, Zhou W, Alazem K, Wang X, Bernstein BE, Bao S, Rich JN. RBPJ maintains brain tumor-initiating cells through CDK9-mediated transcriptional elongation. J Clin Invest. 2016 Jul 01; 126(7):2757-72. PMID: 27322055; PMCID: PMC4922685 [Available on 10/01/16].
    33. Otvos B, Silver DJ, Mulkearns-Hubert EE, Alvarado AG, Turaga SM, Sorensen MD, Rayman P, Flavahan WA, Hale JS, Stoltz K, Sinyuk M, Wu Q, Jarrar A, Kim SH, Fox PL, Nakano I, Rich JN, Ransohoff RM, Finke J, Kristensen BW, Vogelbaum MA, Lathia JD. Cancer Stem Cell-Secreted Macrophage Migration Inhibitory Factor Stimulates Myeloid Derived Suppressor Cell Function and Facilitates Glioblastoma Immune Evasion. Stem Cells. 2016 08; 34(8):2026-39. PMID: 27145382.
      View in: PubMed
    34. Godek KM, Venere M, Wu Q, Mills KD, Hickey WF, Rich JN, Compton DA. Chromosomal Instability Affects the Tumorigenicity of Glioblastoma Tumor-Initiating Cells. Cancer Discov. 2016 05; 6(5):532-45. PMID: 27001151; PMCID: PMC4854766 [Available on 05/01/17].
    35. Dermawan JK, Hitomi M, Silver DJ, Wu Q, Sandlesh P, Sloan AE, Purmal AA, Gurova KV, Rich JN, Lathia JD, Stark GR, Venere M. Pharmacological Targeting of the Histone Chaperone Complex FACT Preferentially Eliminates Glioblastoma Stem Cells and Prolongs Survival in Preclinical Models. Cancer Res. 2016 04 15; 76(8):2432-42. PMID: 26921329; PMCID: PMC4873320 [Available on 04/15/17].
    36. Hubert CG, Rivera M, Spangler LC, Wu Q, Mack SC, Prager BC, Couce M, McLendon RE, Sloan AE, Rich JN. A Three-Dimensional Organoid Culture System Derived from Human Glioblastomas Recapitulates the Hypoxic Gradients and Cancer Stem Cell Heterogeneity of Tumors Found In Vivo. Cancer Res. 2016 04 15; 76(8):2465-77. PMID: 26896279; PMCID: PMC4873351 [Available on 04/15/17].
    37. Mack SC, Hubert CG, Miller TE, Taylor MD, Rich JN. An epigenetic gateway to brain tumor cell identity. Nat Neurosci. 2016 Jan; 19(1):10-9. PMID: 26713744.
      View in: PubMed
    38. Gallo M, Coutinho FJ, Vanner RJ, Gayden T, Mack SC, Murison A, Remke M, Li R, Takayama N, Desai K, Lee L, Lan X, Park NI, Barsyte-Lovejoy D, Smil D, Sturm D, Kushida MM, Head R, Cusimano MD, Bernstein M, Clarke ID, Dick JE, Pfister SM, Rich JN, Arrowsmith CH, Taylor MD, Jabado N, Bazett-Jones DP, Lupien M, Dirks PB. MLL5 Orchestrates a Cancer Self-Renewal State by Repressing the Histone Variant H3.3 and Globally Reorganizing Chromatin. Cancer Cell. 2015 Dec 14; 28(6):715-729. PMID: 26626085.
      View in: PubMed
    39. Rich J. Lending an 'ELPing hand to tumor initiation. J Exp Med. 2015 Nov 16; 212(12):1989. PMID: 26573584; PMCID: PMC4647271.
    40. Zhou W, Cheng L, Shi Y, Ke SQ, Huang Z, Fang X, Chu CW, Xie Q, Bian XW, Rich JN, Bao S. Arsenic trioxide disrupts glioma stem cells via promoting PML degradation to inhibit tumor growth. Oncotarget. 2015 Nov 10; 6(35):37300-15. PMID: 26510911; PMCID: PMC4741931.
    41. Schonberg DL, Miller TE, Wu Q, Flavahan WA, Das NK, Hale JS, Hubert CG, Mack SC, Jarrar AM, Karl RT, Rosager AM, Nixon AM, Tesar PJ, Hamerlik P, Kristensen BW, Horbinski C, Connor JR, Fox PL, Lathia JD, Rich JN. Preferential Iron Trafficking Characterizes Glioblastoma Stem-like Cells. Cancer Cell. 2015 Oct 12; 28(4):441-455. PMID: 26461092; PMCID: PMC4646058 [Available on 10/12/16].
    42. Mack SC, Rich JN, Scacheri PC. "PEAR-ing" Genomic and Epigenomic Analyses for Cancer Gene Discovery. Cancer Discov. 2015 Oct; 5(10):1018-20. PMID: 26429935; PMCID: PMC4608252.
    43. Alvarado AG, Turaga SM, Sathyan P, Mulkearns-Hubert EE, Otvos B, Silver DJ, Hale JS, Flavahan WA, Zinn PO, Sinyuk M, Li M, Guda MR, Velpula KK, Tsung AJ, Nakano I, Vogelbaum MA, Majumder S, Rich JN, Lathia JD. Coordination of self-renewal in glioblastoma by integration of adhesion and microRNA signaling. Neuro Oncol. 2016 05; 18(5):656-66. PMID: 26374689; PMCID: PMC4827035 [Available on 05/01/17].
    44. Venere M, Horbinski C, Crish JF, Jin X, Vasanji A, Major J, Burrows AC, Chang C, Prokop J, Wu Q, Sims PA, Canoll P, Summers MK, Rosenfeld SS, Rich JN. The mitotic kinesin KIF11 is a driver of invasion, proliferation, and self-renewal in glioblastoma. Sci Transl Med. 2015 Sep 09; 7(304):304ra143. PMID: 26355032; PMCID: PMC4743764.
    45. Kim E, Rich J, Karoutas A, Tarlykov P, Cochet E, Malysheva D, Mamchaoui K, Ogryzko V, Pirozhkova I. ZNF555 protein binds to transcriptional activator site of 4qA allele and ANT1: potential implication in Facioscapulohumeral dystrophy. Nucleic Acids Res. 2015 Sep 30; 43(17):8227-42. PMID: 26184877; PMCID: PMC4787827.
    46. Lathia JD, Mack SC, Mulkearns-Hubert EE, Valentim CL, Rich JN. Cancer stem cells in glioblastoma. Genes Dev. 2015 Jun 15; 29(12):1203-17. PMID: 26109046; PMCID: PMC4495393.
    47. Xie Q, Wu Q, Mack SC, Yang K, Kim L, Hubert CG, Flavahan WA, Chu C, Bao S, Rich JN. CDC20 maintains tumor initiating cells. Oncotarget. 2015 May 30; 6(15):13241-54. PMID: 25938542; PMCID: PMC4537011.
    48. Ahluwalia MS, Rich JN. Growth Factor Receptor Fusions Predict Therapeutic Sensitivity. Clin Cancer Res. 2015 Jul 15; 21(14):3105-7. PMID: 25995339.
      View in: PubMed
    49. Thiagarajan PS, Hitomi M, Hale JS, Alvarado AG, Otvos B, Sinyuk M, Stoltz K, Wiechert A, Mulkearns-Hubert E, Jarrar A, Zheng Q, Thomas D, Egelhoff T, Rich JN, Liu H, Lathia JD, Reizes O. Development of a Fluorescent Reporter System to Delineate Cancer Stem Cells in Triple-Negative Breast Cancer. Stem Cells. 2015 Jul; 33(7):2114-2125. PMID: 25827713; PMCID: PMC4494654.
    50. Hitomi M, Deleyrolle LP, Mulkearns-Hubert EE, Jarrar A, Li M, Sinyuk M, Otvos B, Brunet S, Flavahan WA, Hubert CG, Goan W, Hale JS, Alvarado AG, Zhang A, Rohaus M, Oli M, Vedam-Mai V, Fortin JM, Futch HS, Griffith B, Wu Q, Xia CH, Gong X, Ahluwalia MS, Rich JN, Reynolds BA, Lathia JD. Differential connexin function enhances self-renewal in glioblastoma. Cell Rep. 2015 May 19; 11(7):1031-42. PMID: 25959821; PMCID: PMC4502443.
    51. Mathew LK, Huangyang P, Mucaj V, Lee SS, Skuli N, Eisinger-Mathason TS, Biju K, Li B, Venneti S, Lal P, Lathia JD, Rich JN, Keith B, Simon MC. Feedback circuitry between miR-218 repression and RTK activation in glioblastoma. Sci Signal. 2015 May 05; 8(375):ra42. PMID: 25943352; PMCID: PMC4437515.
    52. Xie Q, Wu Q, Horbinski CM, Flavahan WA, Yang K, Zhou W, Dombrowski SM, Huang Z, Fang X, Shi Y, Ferguson AN, Kashatus DF, Bao S, Rich JN. Mitochondrial control by DRP1 in brain tumor initiating cells. Nat Neurosci. 2015 Apr; 18(4):501-10. PMID: 25730670; PMCID: PMC4376639.
    53. Man J, Shoemake JD, Ma T, Rizzo AE, Godley AR, Wu Q, Mohammadi AM, Bao S, Rich JN, Yu JS. Hyperthermia Sensitizes Glioma Stem-like Cells to Radiation by Inhibiting AKT Signaling. Cancer Res. 2015 Apr 15; 75(8):1760-9. PMID: 25712125; PMCID: PMC4401644.
    54. Adorno-Cruz V, Kibria G, Liu X, Doherty M, Junk DJ, Guan D, Hubert C, Venere M, Mulkearns-Hubert E, Sinyuk M, Alvarado A, Caplan AI, Rich J, Gerson SL, Lathia J, Liu H. Cancer stem cells: targeting the roots of cancer, seeds of metastasis, and sources of therapy resistance. Cancer Res. 2015 Mar 15; 75(6):924-9. PMID: 25604264; PMCID: PMC4359955.
    55. Zhou W, Ke SQ, Huang Z, Flavahan W, Fang X, Paul J, Wu L, Sloan AE, McLendon RE, Li X, Rich JN, Bao S. Periostin secreted by glioblastoma stem cells recruits M2 tumour-associated macrophages and promotes malignant growth. Nat Cell Biol. 2015 Feb; 17(2):170-82. PMID: 25580734; PMCID: PMC4312504.
    56. Miller TE, Wang J, Sukhdeo K, Horbinski C, Tesar PJ, Wechsler-Reya RJ, Rich JN. Lgr5 Marks Post-Mitotic, Lineage Restricted Cerebellar Granule Neurons during Postnatal Development. PLoS One. 2014; 9(12):e114433. PMID: 25493560; PMCID: PMC4262395.
    57. Grace SM, Rich J, Chin W, Rodriguez HP. Fidelity of implementation to a care team redesign and improved outcomes of diabetes care. Int J Qual Health Care. 2015 Feb; 27(1):60-6. PMID: 25431469.
      View in: PubMed
    58. Stoltz K, Sinyuk M, Hale JS, Wu Q, Otvos B, Walker K, Vasanji A, Rich JN, Hjelmeland AB, Lathia JD. Development of a Sox2 reporter system modeling cellular heterogeneity in glioma. Neuro Oncol. 2015 Mar; 17(3):361-71. PMID: 25416826; PMCID: PMC4483103.
    59. Man J, Shoemake J, Zhou W, Fang X, Wu Q, Rizzo A, Prayson R, Bao S, Rich JN, Yu JS. Sema3C promotes the survival and tumorigenicity of glioma stem cells through Rac1 activation. Cell Rep. 2014 Dec 11; 9(5):1812-1826. PMID: 25464848.
      View in: PubMed
    60. Xie Q, Flavahan WA, Bao S, Rich J. The tailless root of glioma: cancer stem cells. Cell Stem Cell. 2014 Aug 07; 15(2):114-6. PMID: 25105574; PMCID: PMC4239656.
    61. Fang X, Huang Z, Zhou W, Wu Q, Sloan AE, Ouyang G, McLendon RE, Yu JS, Rich JN, Bao S. The zinc finger transcription factor ZFX is required for maintaining the tumorigenic potential of glioblastoma stem cells. Stem Cells. 2014 Aug; 32(8):2033-47. PMID: 24831540; PMCID: PMC4349564.
    62. Hale JS, Otvos B, Sinyuk M, Alvarado AG, Hitomi M, Stoltz K, Wu Q, Flavahan W, Levison B, Johansen ML, Schmitt D, Neltner JM, Huang P, Ren B, Sloan AE, Silverstein RL, Gladson CL, DiDonato JA, Brown JM, McIntyre T, Hazen SL, Horbinski C, Rich JN, Lathia JD. Cancer stem cell-specific scavenger receptor CD36 drives glioblastoma progression. Stem Cells. 2014 Jul; 32(7):1746-58. PMID: 24737733; PMCID: PMC4063873.
    63. Bai Y, Lathia JD, Zhang P, Flavahan W, Rich JN, Mattson MP. Molecular targeting of TRF2 suppresses the growth and tumorigenesis of glioblastoma stem cells. Glia. 2014 Oct; 62(10):1687-98. PMID: 24909307.
      View in: PubMed
    64. Thorne AH, Meisen WH, Russell L, Yoo JY, Bolyard CM, Lathia JD, Rich J, Puduvalli VK, Mao H, Yu J, Caligiuri MA, Tridandapani S, Kaur B. Role of cysteine-rich 61 protein (CCN1) in macrophage-mediated oncolytic herpes simplex virus clearance. Mol Ther. 2014 Sep; 22(9):1678-87. PMID: 24895995; PMCID: PMC4435480.
    65. Ferrarese R, Harsh GR, Yadav AK, Bug E, Maticzka D, Reichardt W, Dombrowski SM, Miller TE, Masilamani AP, Dai F, Kim H, Hadler M, Scholtens DM, Yu IL, Beck J, Srinivasasainagendra V, Costa F, Baxan N, Pfeifer D, von Elverfeldt D, Backofen R, Weyerbrock A, Duarte CW, He X, Prinz M, Chandler JP, Vogel H, Chakravarti A, Rich JN, Carro MS, Bredel M. Lineage-specific splicing of a brain-enriched alternative exon promotes glioblastoma progression. J Clin Invest. 2014 Jul; 124(7):2861-76. PMID: 24865424; PMCID: PMC4071411.
    66. Yan K, Wu Q, Yan DH, Lee CH, Rahim N, Tritschler I, DeVecchio J, Kalady MF, Hjelmeland AB, Rich JN. Glioma cancer stem cells secrete Gremlin1 to promote their maintenance within the tumor hierarchy. Genes Dev. 2014 May 15; 28(10):1085-100. PMID: 24788093; PMCID: PMC4035537.
    67. Fan Y, Potdar AA, Gong Y, Eswarappa SM, Donnola S, Lathia JD, Hambardzumyan D, Rich JN, Fox PL. Profilin-1 phosphorylation directs angiocrine expression and glioblastoma progression through HIF-1a accumulation. Nat Cell Biol. 2014 May; 16(5):445-56. PMID: 24747440; PMCID: PMC4036069.
    68. Camp CH, Lee YJ, Heddleston JM, Hartshorn CM, Hight Walker AR, Rich JN, Lathia JD, Cicerone MT. High-Speed Coherent Raman Fingerprint Imaging of Biological Tissues. Nat Photonics. 2014; 8:627-634. PMID: 25621002.
      View in: PubMed
    69. Lathia JD, Li M, Sinyuk M, Alvarado AG, Flavahan WA, Stoltz K, Rosager AM, Hale J, Hitomi M, Gallagher J, Wu Q, Martin J, Vidal JG, Nakano I, Dahlrot RH, Hansen S, McLendon RE, Sloan AE, Bao S, Hjelmeland AB, Carson CT, Naik UP, Kristensen B, Rich JN. High-throughput flow cytometry screening reveals a role for junctional adhesion molecule a as a cancer stem cell maintenance factor. Cell Rep. 2014 Jan 16; 6(1):117-29. PMID: 24373972; PMCID: PMC3899718.
    70. Mathew LK, Skuli N, Mucaj V, Lee SS, Zinn PO, Sathyan P, Imtiyaz HZ, Zhang Z, Davuluri RV, Rao S, Venneti S, Lal P, Lathia JD, Rich JN, Keith B, Minn AJ, Simon MC. miR-218 opposes a critical RTK-HIF pathway in mesenchymal glioblastoma. Proc Natl Acad Sci U S A. 2014 Jan 07; 111(1):291-6. PMID: 24368849; PMCID: PMC3890843.
    71. Lotti F, Jarrar AM, Pai RK, Hitomi M, Lathia J, Mace A, Gantt GA, Sukhdeo K, DeVecchio J, Vasanji A, Leahy P, Hjelmeland AB, Kalady MF, Rich JN. Chemotherapy activates cancer-associated fibroblasts to maintain colorectal cancer-initiating cells by IL-17A. J Exp Med. 2013 Dec 16; 210(13):2851-72. PMID: 24323355; PMCID: PMC3865474.
    72. Yan K, Yang K, Rich JN. The evolving landscape of glioblastoma stem cells. Curr Opin Neurol. 2013 Dec; 26(6):701-7. PMID: 24152818; PMCID: PMC4031658.
    73. Sukhdeo K, Koch CE, Miller TE, Zhou H, Rivera M, Yan K, Cepko CL, Lathia JD, Rich JN. The Lgr5 transgene is expressed specifically in glycinergic amacrine cells in the mouse retina. Exp Eye Res. 2014 Feb; 119:106-10. PMID: 24246263; PMCID: PMC3986349.
    74. Zheng Q, Banaszak L, Fracci S, Basali D, Dunlap SM, Hursting SD, Rich JN, Hjlemeland AB, Vasanji A, Berger NA, Lathia JD, Reizes O. Leptin receptor maintains cancer stem-like properties in triple negative breast cancer cells. Endocr Relat Cancer. 2013 Dec; 20(6):797-808. PMID: 24025407; PMCID: PMC3843956.
    75. Schonberg DL, Bao S, Rich JN. Genomics informs glioblastoma biology. Nat Genet. 2013 Oct; 45(10):1105-7. PMID: 24071842.
      View in: PubMed
    76. Flavahan WA, Wu Q, Hitomi M, Rahim N, Kim Y, Sloan AE, Weil RJ, Nakano I, Sarkaria JN, Stringer BW, Day BW, Li M, Lathia JD, Rich JN, Hjelmeland AB. Brain tumor initiating cells adapt to restricted nutrition through preferential glucose uptake. Nat Neurosci. 2013 Oct; 16(10):1373-82. PMID: 23995067; PMCID: PMC3930177.
    77. Schonberg DL, Venere M, Rich JN. Changing the fate of cancer, one splice at a time. Proc Natl Acad Sci U S A. 2013 Sep 03; 110(36):14510-1. PMID: 23969832; PMCID: PMC3767506.
    78. Cao Y, Eble JM, Moon E, Yuan H, Weitzel DH, Landon CD, Nien CY, Hanna G, Rich JN, Provenzale JM, Dewhirst MW. Tumor cells upregulate normoxic HIF-1a in response to doxorubicin. Cancer Res. 2013 Oct 15; 73(20):6230-42. PMID: 23959856; PMCID: PMC3800255.
    79. Schulte JD, Srikanth M, Das S, Zhang J, Lathia JD, Yin L, Rich JN, Olson EC, Kessler JA, Chenn A. Cadherin-11 regulates motility in normal cortical neural precursors and glioblastoma. PLoS One. 2013; 8(8):e70962. PMID: 23951053.
      View in: PubMed
    80. Liu WM, Huang P, Kar N, Burgett M, Muller-Greven G, Nowacki AS, Distelhorst CW, Lathia JD, Rich JN, Kappes JC, Gladson CL. Lyn facilitates glioblastoma cell survival under conditions of nutrient deprivation by promoting autophagy. PLoS One. 2013; 8(8):e70804. PMID: 23936469; PMCID: PMC3732228.
    81. Schonberg DL, Lubelski D, Miller TE, Rich JN. Brain tumor stem cells: Molecular characteristics and their impact on therapy. Mol Aspects Med. 2014 Oct; 39:82-101. PMID: 23831316; PMCID: PMC3866208.
    82. Hale JS, Sinyuk M, Rich JN, Lathia JD. Decoding the cancer stem cell hypothesis in glioblastoma. CNS Oncol. 2013 Jul; 2(4):319-30. PMID: 24379973; PMCID: PMC3873749.
    83. Kim Y, Wu Q, Hamerlik P, Hitomi M, Sloan AE, Barnett GH, Weil RJ, Leahy P, Hjelmeland AB, Rich JN. Aptamer identification of brain tumor-initiating cells. Cancer Res. 2013 Aug 01; 73(15):4923-36. PMID: 23796560; PMCID: PMC3933790.
    84. Kim E, Kim M, Woo DH, Shin Y, Shin J, Chang N, Oh YT, Kim H, Rheey J, Nakano I, Lee C, Joo KM, Rich JN, Nam DH, Lee J. Phosphorylation of EZH2 activates STAT3 signaling via STAT3 methylation and promotes tumorigenicity of glioblastoma stem-like cells. Cancer Cell. 2013 Jun 10; 23(6):839-52. PMID: 23684459; PMCID: PMC4109796.
    85. Cheng L, Huang Z, Zhou W, Wu Q, Donnola S, Liu JK, Fang X, Sloan AE, Mao Y, Lathia JD, Min W, McLendon RE, Rich JN, Bao S. Glioblastoma stem cells generate vascular pericytes to support vessel function and tumor growth. Cell. 2013 Mar 28; 153(1):139-52. PMID: 23540695; PMCID: PMC3638263.
    86. Xu C, Xie D, Yu SC, Yang XJ, He LR, Yang J, Ping YF, Wang B, Yang L, Xu SL, Cui W, Wang QL, Fu WJ, Liu Q, Qian C, Cui YH, Rich JN, Kung HF, Zhang X, Bian XW. ß-Catenin/POU5F1/SOX2 transcription factor complex mediates IGF-I receptor signaling and predicts poor prognosis in lung adenocarcinoma. Cancer Res. 2013 May 15; 73(10):3181-9. PMID: 23539445.
      View in: PubMed
    87. Venere M, Lathia JD, Rich JN. Growth factor receptors define cancer hierarchies. Cancer Cell. 2013 Feb 11; 23(2):135-7. PMID: 23410969; PMCID: PMC3616317.
    88. Venere M, Miller TE, Rich JN. Mitotic control of cancer stem cells. Cancer Discov. 2013 Feb; 3(2):141-4. PMID: 23400473; PMCID: PMC3616319.
    89. Sukhdeo K, Paramban RI, Vidal JG, Elia J, Martin J, Rivera M, Carrasco DR, Jarrar A, Kalady MF, Carson CT, Balderas R, Hjelmeland AB, Lathia JD, Rich JN. Multiplex flow cytometry barcoding and antibody arrays identify surface antigen profiles of primary and metastatic colon cancer cell lines. PLoS One. 2013; 8(1):e53015. PMID: 23308131; PMCID: PMC3538639.
    90. Lathia JD, Li M, Hall PE, Gallagher J, Hale JS, Wu Q, Venere M, Levy E, Rani MR, Huang P, Bae E, Selfridge J, Cheng L, Guvenc H, McLendon RE, Nakano I, Sloan AE, Phillips HS, Lai A, Gladson CL, Bredel M, Bao S, Hjelmeland AB, Rich JN. Laminin alpha 2 enables glioblastoma stem cell growth. Ann Neurol. 2012 Nov; 72(5):766-78. PMID: 23280793; PMCID: PMC3615417.
    91. Eyler CE, Rich JN. Looking in the miR-ror: TGF-ß-mediated activation of NF-?B in glioma. J Clin Invest. 2012 Oct; 122(10):3473-5. PMID: 23006324; PMCID: PMC3461933.
    92. Schonberg DL, Bao S, Rich JN. TRP-ing up brain tumors. Nat Med. 2012 Aug; 18(8):1175-6. PMID: 22869181.
      View in: PubMed
    93. Li M, Hale JS, Rich JN, Ransohoff RM, Lathia JD. Chemokine CXCL12 in neurodegenerative diseases: an SOS signal for stem cell-based repair. Trends Neurosci. 2012 Oct; 35(10):619-28. PMID: 22784557; PMCID: PMC3461091.
    94. Hjelmeland AB, Rich JN. The quest for self-identity: not all cancer stem cells are the same. Clin Cancer Res. 2012 Jul 01; 18(13):3495-8. PMID: 22711710; PMCID: PMC3389128.
    95. Rich J, Raviv A, Raviv N, Brietzke SE. All-cause mortality and obstructive sleep apnea severity revisited. Otolaryngol Head Neck Surg. 2012 Sep; 147(3):583-7. PMID: 22687326.
      View in: PubMed
    96. Kim Y, Kim E, Wu Q, Guryanova O, Hitomi M, Lathia JD, Serwanski D, Sloan AE, Weil RJ, Lee J, Nishiyama A, Bao S, Hjelmeland AB, Rich JN. Platelet-derived growth factor receptors differentially inform intertumoral and intratumoral heterogeneity. Genes Dev. 2012 Jun 01; 26(11):1247-62. PMID: 22661233; PMCID: PMC3371412.
    97. Joo KM, Jin J, Kim E, Ho Kim K, Kim Y, Gu Kang B, Kang YJ, Lathia JD, Cheong KH, Song PH, Kim H, Seol HJ, Kong DS, Lee JI, Rich JN, Lee J, Nam DH. MET signaling regulates glioblastoma stem cells. Cancer Res. 2012 Aug 01; 72(15):3828-38. PMID: 22617325.
      View in: PubMed
    98. Lathia JD, Rich JN. Holding on to stemness. Nat Cell Biol. 2012 May 02; 14(5):450-2. PMID: 22552145.
      View in: PubMed
    99. Reardon DA, Vredenburgh JJ, Desjardins A, Peters KB, Sathornsumetee S, Threatt S, Sampson JH, Herndon JE, Coan A, McSherry F, Rich JN, McLendon RE, Zhang S, Friedman HS. Phase 1 trial of dasatinib plus erlotinib in adults with recurrent malignant glioma. J Neurooncol. 2012 Jul; 108(3):499-506. PMID: 22407177; PMCID: PMC3690584.
    100. Huang P, Rani MR, Ahluwalia MS, Bae E, Prayson RA, Weil RJ, Nowacki AS, Hedayat H, Sloan AE, Lathia JD, Rich JN, Tipps R, Gladson CL. Endothelial expression of TNF receptor-1 generates a proapoptotic signal inhibited by integrin a6ß1 in glioblastoma. Cancer Res. 2012 Mar 15; 72(6):1428-37. PMID: 22396498; PMCID: PMC3428239.
    101. Hamerlik P, Lathia JD, Rasmussen R, Wu Q, Bartkova J, Lee M, Moudry P, Bartek J, Fischer W, Lukas J, Rich JN, Bartek J. Autocrine VEGF-VEGFR2-Neuropilin-1 signaling promotes glioma stem-like cell viability and tumor growth. J Exp Med. 2012 Mar 12; 209(3):507-20. PMID: 22393126; PMCID: PMC3302235.
    102. Reardon DA, Desjardins A, Vredenburgh JJ, Herndon JE, Coan A, Gururangan S, Peters KB, McLendon R, Sathornsumetee S, Rich JN, Lipp ES, Janney D, Friedman HS. Phase II study of Gleevec plus hydroxyurea in adults with progressive or recurrent low-grade glioma. Cancer. 2012 Oct 01; 118(19):4759-67. PMID: 22371319; PMCID: PMC3748946.
    103. Sathornsumetee S, Rich JN. Molecularly targeted therapy in neuro-oncology. Handb Clin Neurol. 2012; 104:255-78. PMID: 22230448.
      View in: PubMed
    104. Chin BB, Hjelemand A, Rich J, Song H, Lascola C, Storms R, McLendon R, Reiman R, Greer KL, Metzler SD, McDougald D, Dai D, Vaidyanathan G. Synthesis and preliminary evaluation of n.c.a. iodoquine: a novel radiotracer with high uptake in cells with high ALDH1 expression. Curr Radiopharm. 2012 Jan; 5(1):47-58. PMID: 21864242.
      View in: PubMed
    105. Wang J, Sullenger BA, Rich JN. Notch signaling in cancer stem cells. Adv Exp Med Biol. 2012; 727:174-85. PMID: 22399347.
      View in: PubMed
    106. Hjelmeland AB, Lathia JD, Sathornsumetee S, Rich JN. Twisted tango: brain tumor neurovascular interactions. Nat Neurosci. 2011 Oct 26; 14(11):1375-81. PMID: 22030548; PMCID: PMC3615423.
    107. Reardon DA, Herndon JE, Peters K, Desjardins A, Coan A, Lou E, Sumrall A, Turner S, Sathornsumetee S, Rich JN, Boulton S, Lipp ES, Friedman HS, Vredenburgh JJ. Outcome after bevacizumab clinical trial therapy among recurrent grade III malignant glioma patients. J Neurooncol. 2012 Mar; 107(1):213-21. PMID: 21997879; PMCID: PMC3403724.
    108. Reardon DA, Cloughesy T, Rich J, Alfred Yung WK, Yung L, DiLea C, Huang J, Dugan M, Mietlowski W, Maes A, Conrad C. Pharmacokinetic drug interaction between AEE788 and RAD001 causing thrombocytopenia in patients with glioblastoma. Cancer Chemother Pharmacol. 2012 Jan; 69(1):281-7. PMID: 21984222.
      View in: PubMed
    109. Lathia JD, Gallagher J, Myers JT, Li M, Vasanji A, McLendon RE, Hjelmeland AB, Huang AY, Rich JN. Direct in vivo evidence for tumor propagation by glioblastoma cancer stem cells. PLoS One. 2011; 6(9):e24807. PMID: 21961046; PMCID: PMC3178553.
    110. Hanses F, Park S, Rich J, Lee JC. Reduced neutrophil apoptosis in diabetic mice during staphylococcal infection leads to prolonged Tnfa production and reduced neutrophil clearance. PLoS One. 2011; 6(8):e23633. PMID: 21912601; PMCID: PMC3166063.
    111. Rich J, Raviv A, Raviv N, Brietzke SE. An epidemiologic study of snoring and all-cause mortality. Otolaryngol Head Neck Surg. 2011 Aug; 145(2):341-6. PMID: 21493281.
      View in: PubMed
    112. Sukhdeo K, Hambardzumyan D, Rich JN. Glioma development: where did it all go wrong? Cell. 2011 Jul 22; 146(2):187-8. PMID: 21784240.
      View in: PubMed
    113. Zheng Q, Dunlap SM, Zhu J, Downs-Kelly E, Rich J, Hursting SD, Berger NA, Reizes O. Leptin deficiency suppresses MMTV-Wnt-1 mammary tumor growth in obese mice and abrogates tumor initiating cell survival. Endocr Relat Cancer. 2011 Aug; 18(4):491-503. PMID: 21636700; PMCID: PMC3197719.
    114. Reardon DA, Vredenburgh JJ, Coan A, Desjardins A, Peters KB, Gururangan S, Sathornsumetee S, Rich JN, Herndon JE, Friedman HS. Phase I study of sunitinib and irinotecan for patients with recurrent malignant glioma. J Neurooncol. 2011 Dec; 105(3):621-7. PMID: 21744079; PMCID: PMC3748953.
    115. Eyler CE, Wu Q, Yan K, MacSwords JM, Chandler-Militello D, Misuraca KL, Lathia JD, Forrester MT, Lee J, Stamler JS, Goldman SA, Bredel M, McLendon RE, Sloan AE, Hjelmeland AB, Rich JN. Glioma stem cell proliferation and tumor growth are promoted by nitric oxide synthase-2. Cell. 2011 Jul 08; 146(1):53-66. PMID: 21729780; PMCID: PMC3144745.
    116. Mathieu J, Zhang Z, Zhou W, Wang AJ, Heddleston JM, Pinna CM, Hubaud A, Stadler B, Choi M, Bar M, Tewari M, Liu A, Vessella R, Rostomily R, Born D, Horwitz M, Ware C, Blau CA, Cleary MA, Rich JN, Ruohola-Baker H. HIF induces human embryonic stem cell markers in cancer cells. Cancer Res. 2011 Jul 01; 71(13):4640-52. PMID: 21712410; PMCID: PMC3129496.
    117. Lathia JD, Venere M, Rao MS, Rich JN. Seeing is believing: are cancer stem cells the Loch Ness monster of tumor biology? Stem Cell Rev. 2011 Jun; 7(2):227-37. PMID: 20957452; PMCID: PMC3093710.
    118. Lathia JD, Heddleston JM, Venere M, Rich JN. Deadly teamwork: neural cancer stem cells and the tumor microenvironment. Cell Stem Cell. 2011 May 06; 8(5):482-5. PMID: 21549324; PMCID: PMC3494093.
    119. Venere M, Fine HA, Dirks PB, Rich JN. Cancer stem cells in gliomas: identifying and understanding the apex cell in cancer's hierarchy. Glia. 2011 Aug; 59(8):1148-54. PMID: 21547954; PMCID: PMC3107874.
    120. Guryanova OA, Wu Q, Cheng L, Lathia JD, Huang Z, Yang J, MacSwords J, Eyler CE, McLendon RE, Heddleston JM, Shou W, Hambardzumyan D, Lee J, Hjelmeland AB, Sloan AE, Bredel M, Stark GR, Rich JN, Bao S. Nonreceptor tyrosine kinase BMX maintains self-renewal and tumorigenic potential of glioblastoma stem cells by activating STAT3. Cancer Cell. 2011 Apr 12; 19(4):498-511. PMID: 21481791; PMCID: PMC3076106.
    121. Cheng L, Wu Q, Guryanova OA, Huang Z, Huang Q, Rich JN, Bao S. Elevated invasive potential of glioblastoma stem cells. Biochem Biophys Res Commun. 2011 Mar 25; 406(4):643-8. PMID: 21371437; PMCID: PMC3065536.
    122. Cheng L, Wu Q, Huang Z, Guryanova OA, Huang Q, Shou W, Rich JN, Bao S. L1CAM regulates DNA damage checkpoint response of glioblastoma stem cells through NBS1. EMBO J. 2011 Mar 02; 30(5):800-13. PMID: 21297581; PMCID: PMC3049209.
    123. Huang Z, Wu Q, Guryanova OA, Cheng L, Shou W, Rich JN, Bao S. Deubiquitylase HAUSP stabilizes REST and promotes maintenance of neural progenitor cells. Nat Cell Biol. 2011 Feb; 13(2):142-52. PMID: 21258371; PMCID: PMC3076066.
    124. Hjelmeland AB, Rich JN. Molecular targeting of neural cancer stem cells: TTAGGG, you're it! Clin Cancer Res. 2011 Jan 01; 17(1):3-5. PMID: 21208901; PMCID: PMC3099413.
    125. Forrester MT, Eyler CE, Rich JN. Bacterial flavohemoglobin: a molecular tool to probe mammalian nitric oxide biology. Biotechniques. 2011 Jan; 50(1):41-5. PMID: 21231921; PMCID: PMC3096140.
    126. Heddleston JM, Hitomi M, Venere M, Flavahan WA, Yang K, Kim Y, Minhas S, Rich JN, Hjelmeland AB. Glioma stem cell maintenance: the role of the microenvironment. Curr Pharm Des. 2011; 17(23):2386-401. PMID: 21827414; PMCID: PMC3615428.
    127. Shats I, Gatza ML, Chang JT, Mori S, Wang J, Rich J, Nevins JR. Using a stem cell-based signature to guide therapeutic selection in cancer. Cancer Res. 2011 Mar 01; 71(5):1772-80. PMID: 21169407; PMCID: PMC3049992.
    128. McLendon RE, Rich JN. Glioblastoma Stem Cells: A Neuropathologist's View. J Oncol. 2011; 2011:397195. PMID: 21052560; PMCID: PMC2971570.
    129. Sheehan JP, Shaffrey ME, Gupta B, Larner J, Rich JN, Park DM. Improving the radiosensitivity of radioresistant and hypoxic glioblastoma. Future Oncol. 2010 Oct; 6(10):1591-601. PMID: 21062158.
      View in: PubMed
    130. Reardon DA, Desjardins A, Peters K, Gururangan S, Sampson J, Rich JN, McLendon R, Herndon JE, Marcello J, Threatt S, Friedman AH, Vredenburgh JJ, Friedman HS. Phase II study of metronomic chemotherapy with bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy. J Neurooncol. 2011 Jun; 103(2):371-9. PMID: 20853132; PMCID: PMC3102515.
    131. Sathornsumetee S, Desjardins A, Vredenburgh JJ, McLendon RE, Marcello J, Herndon JE, Mathe A, Hamilton M, Rich JN, Norfleet JA, Gururangan S, Friedman HS, Reardon DA. Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma. Neuro Oncol. 2010 Dec; 12(12):1300-10. PMID: 20716591; PMCID: PMC3018944.
    132. Weinberg R, Fisher DE, Rich J. Dynamic and transient cancer stem cells nurture melanoma. Nat Med. 2010 Jul; 16(7):758. PMID: 20613753.
      View in: PubMed
    133. Cheng L, Bao S, Rich JN. Potential therapeutic implications of cancer stem cells in glioblastoma. Biochem Pharmacol. 2010 Sep 01; 80(5):654-65. PMID: 20457135; PMCID: PMC2897968.
    134. Lathia JD, Gallagher J, Heddleston JM, Wang J, Eyler CE, Macswords J, Wu Q, Vasanji A, McLendon RE, Hjelmeland AB, Rich JN. Integrin alpha 6 regulates glioblastoma stem cells. Cell Stem Cell. 2010 May 07; 6(5):421-32. PMID: 20452317; PMCID: PMC2884275.
    135. Nadeau DP, Rich JN, Brietzke SE. Informed consent in pediatric surgery: Do parents understand the risks? Arch Otolaryngol Head Neck Surg. 2010 Mar; 136(3):265-9. PMID: 20231645.
      View in: PubMed
    136. Hjelmeland AB, Wu Q, Wickman S, Eyler C, Heddleston J, Shi Q, Lathia JD, Macswords J, Lee J, McLendon RE, Rich JN. Targeting A20 decreases glioma stem cell survival and tumor growth. PLoS Biol. 2010 Feb 23; 8(2):e1000319. PMID: 20186265; PMCID: PMC2826371.
    137. Park DM, Sathornsumetee S, Rich JN. Medical oncology: treatment and management of malignant gliomas. Nat Rev Clin Oncol. 2010 Feb; 7(2):75-7. PMID: 20118976.
      View in: PubMed
    138. Wang J, Wakeman TP, Lathia JD, Hjelmeland AB, Wang XF, White RR, Rich JN, Sullenger BA. Notch promotes radioresistance of glioma stem cells. Stem Cells. 2010 Jan; 28(1):17-28. PMID: 19921751; PMCID: PMC2825687.
    139. Li Z, Rich JN. Hypoxia and hypoxia inducible factors in cancer stem cell maintenance. Curr Top Microbiol Immunol. 2010; 345:21-30. PMID: 20582533.
      View in: PubMed
    140. Cao Y, Lathia JD, Eyler CE, Wu Q, Li Z, Wang H, McLendon RE, Hjelmeland AB, Rich JN. Erythropoietin Receptor Signaling Through STAT3 Is Required For Glioma Stem Cell Maintenance. Genes Cancer. 2010 Jan 01; 1(1):50-61. PMID: 20657792.
      View in: PubMed
    141. Chigurupati S, Venkataraman R, Barrera D, Naganathan A, Madan M, Paul L, Pattisapu JV, Kyriazis GA, Sugaya K, Bushnev S, Lathia JD, Rich JN, Chan SL. Receptor channel TRPC6 is a key mediator of Notch-driven glioblastoma growth and invasiveness. Cancer Res. 2010 Jan 01; 70(1):418-27. PMID: 20028870.
      View in: PubMed
    142. Heddleston JM, Li Z, McLendon RE, Hjelmeland AB, Rich JN. The hypoxic microenvironment maintains glioblastoma stem cells and promotes reprogramming towards a cancer stem cell phenotype. Cell Cycle. 2009 Oct 15; 8(20):3274-84. PMID: 19770585; PMCID: PMC2825672.
    143. Wang H, Lathia JD, Wu Q, Wang J, Li Z, Heddleston JM, Eyler CE, Elderbroom J, Gallagher J, Schuschu J, MacSwords J, Cao Y, McLendon RE, Wang XF, Hjelmeland AB, Rich JN. Targeting interleukin 6 signaling suppresses glioma stem cell survival and tumor growth. Stem Cells. 2009 Oct; 27(10):2393-404. PMID: 19658188; PMCID: PMC2825688.
    144. Zhang P, Lathia JD, Flavahan WA, Rich JN, Mattson MP. Squelching glioblastoma stem cells by targeting REST for proteasomal degradation. Trends Neurosci. 2009 Nov; 32(11):559-65. PMID: 19748686.
      View in: PubMed
    145. Affronti ML, Heery CR, Herndon JE, Rich JN, Reardon DA, Desjardins A, Vredenburgh JJ, Friedman AH, Bigner DD, Friedman HS. Overall survival of newly diagnosed glioblastoma patients receiving carmustine wafers followed by radiation and concurrent temozolomide plus rotational multiagent chemotherapy. Cancer. 2009 Aug 01; 115(15):3501-11. PMID: 19514083.
      View in: PubMed
    146. Park DM, Rich JN. Biology of glioma cancer stem cells. Mol Cells. 2009 Jul 31; 28(1):7-12. PMID: 19655094.
      View in: PubMed
    147. Schilling SH, Hjelmeland AB, Radiloff DR, Liu IM, Wakeman TP, Fielhauer JR, Foster EH, Lathia JD, Rich JN, Wang XF, Datto MB. NDRG4 is required for cell cycle progression and survival in glioblastoma cells. J Biol Chem. 2009 Sep 11; 284(37):25160-9. PMID: 19592488; PMCID: PMC2757219.
    148. Li Z, Bao S, Wu Q, Wang H, Eyler C, Sathornsumetee S, Shi Q, Cao Y, Lathia J, McLendon RE, Hjelmeland AB, Rich JN. Hypoxia-inducible factors regulate tumorigenic capacity of glioma stem cells. Cancer Cell. 2009 Jun 02; 15(6):501-13. PMID: 19477429; PMCID: PMC2693960.
    149. Quinn JA, Jiang SX, Reardon DA, Desjardins A, Vredenburgh JJ, Rich JN, Gururangan S, Friedman AH, Bigner DD, Sampson JH, McLendon RE, Herndon JE, Walker A, Friedman HS. Phase I trial of temozolomide plus O6-benzylguanine 5-day regimen with recurrent malignant glioma. Neuro Oncol. 2009 Oct; 11(5):556-61. PMID: 19289491; PMCID: PMC2765345.
    150. Li Z, Wang H, Eyler CE, Hjelmeland AB, Rich JN. Turning cancer stem cells inside out: an exploration of glioma stem cell signaling pathways. J Biol Chem. 2009 Jun 19; 284(25):16705-9. PMID: 19286664; PMCID: PMC2719304.
    151. Quinn JA, Jiang SX, Reardon DA, Desjardins A, Vredenburgh JJ, Rich JN, Gururangan S, Friedman AH, Bigner DD, Sampson JH, McLendon RE, Herndon JE, Walker A, Friedman HS. Phase II trial of temozolomide plus o6-benzylguanine in adults with recurrent, temozolomide-resistant malignant glioma. J Clin Oncol. 2009 Mar 10; 27(8):1262-7. PMID: 19204199; PMCID: PMC2667825.
    152. Quinn JA, Jiang SX, Carter J, Reardon DA, Desjardins A, Vredenburgh JJ, Rich JN, Gururangan S, Friedman AH, Bigner DD, Sampson JH, McLendon RE, Herndon JE, Threatt S, Friedman HS. Phase II trial of Gliadel plus O6-benzylguanine in adults with recurrent glioblastoma multiforme. Clin Cancer Res. 2009 Feb 01; 15(3):1064-8. PMID: 19188181; PMCID: PMC2710963.
    153. Park S, Rich J, Hanses F, Lee JC. Defects in innate immunity predispose C57BL/6J-Leprdb/Leprdb mice to infection by Staphylococcus aureus. Infect Immun. 2009 Mar; 77(3):1008-14. PMID: 19103772; PMCID: PMC2643648.
    154. Wang J, Wang H, Li Z, Wu Q, Lathia JD, McLendon RE, Hjelmeland AB, Rich JN. c-Myc is required for maintenance of glioma cancer stem cells. PLoS One. 2008; 3(11):e3769. PMID: 19020659; PMCID: PMC2582454.
    155. Desjardins A, Reardon DA, Herndon JE, Marcello J, Quinn JA, Rich JN, Sathornsumetee S, Gururangan S, Sampson J, Bailey L, Bigner DD, Friedman AH, Friedman HS, Vredenburgh JJ. Bevacizumab plus irinotecan in recurrent WHO grade 3 malignant gliomas. Clin Cancer Res. 2008 Nov 01; 14(21):7068-73. PMID: 18981004; PMCID: PMC3671765.
    156. Sathornsumetee S, Rich JN. Designer therapies for glioblastoma multiforme. Ann N Y Acad Sci. 2008 Oct; 1142:108-32. PMID: 18990124.
      View in: PubMed
    157. Eyler CE, Foo WC, LaFiura KM, McLendon RE, Hjelmeland AB, Rich JN. Brain cancer stem cells display preferential sensitivity to Akt inhibition. Stem Cells. 2008 Dec; 26(12):3027-36. PMID: 18802038; PMCID: PMC2739007.
    158. Gururangan S, Krauser J, Watral MA, Driscoll T, Larrier N, Reardon DA, Rich JN, Quinn JA, Vredenburgh JJ, Desjardins A, McLendon RE, Fuchs H, Kurtzberg J, Friedman HS. Efficacy of high-dose chemotherapy or standard salvage therapy in patients with recurrent medulloblastoma. Neuro Oncol. 2008 Oct; 10(5):745-51. PMID: 18755919; PMCID: PMC2666251.
    159. Bao S, Wu Q, Li Z, Sathornsumetee S, Wang H, McLendon RE, Hjelmeland AB, Rich JN. Targeting cancer stem cells through L1CAM suppresses glioma growth. Cancer Res. 2008 Aug 01; 68(15):6043-8. PMID: 18676824; PMCID: PMC2739001.
    160. Eyler CE, Rich JN. Survival of the fittest: cancer stem cells in therapeutic resistance and angiogenesis. J Clin Oncol. 2008 Jun 10; 26(17):2839-45. PMID: 18539962; PMCID: PMC2739000.
    161. Rich JN. The Implications of the Cancer Stem Cell Hypothesis for Neuro-Oncology and Neurology. Future Neurol. 2008 May 01; 3(3):265-273. PMID: 19763280.
      View in: PubMed
    162. Reardon DA, Desjardins A, Vredenburgh JJ, Sathornsumetee S, Rich JN, Quinn JA, Lagattuta TF, Egorin MJ, Gururangan S, McLendon R, Herndon JE, Friedman AH, Salvado AJ, Friedman HS. Safety and pharmacokinetics of dose-intensive imatinib mesylate plus temozolomide: phase 1 trial in adults with malignant glioma. Neuro Oncol. 2008 Jun; 10(3):330-40. PMID: 18359865; PMCID: PMC2563055.
    163. Reardon DA, Zalutsky MR, Akabani G, Coleman RE, Friedman AH, Herndon JE, McLendon RE, Pegram CN, Quinn JA, Rich JN, Vredenburgh JJ, Desjardins A, Guruangan S, Boulton S, Raynor RH, Dowell JM, Wong TZ, Zhao XG, Friedman HS, Bigner DD. A pilot study: 131I-antitenascin monoclonal antibody 81c6 to deliver a 44-Gy resection cavity boost. Neuro Oncol. 2008 Apr; 10(2):182-9. PMID: 18287339; PMCID: PMC2613820.
    164. Reardon DA, Desjardins A, Rich JN, Vredenburgh JJ. The emerging role of anti-angiogenic therapy for malignant glioma. Curr Treat Options Oncol. 2008 Feb; 9(1):1-22. PMID: 18256938.
      View in: PubMed
    165. Sathornsumetee S, Cao Y, Marcello JE, Herndon JE, McLendon RE, Desjardins A, Friedman HS, Dewhirst MW, Vredenburgh JJ, Rich JN. Tumor angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with bevacizumab and irinotecan. J Clin Oncol. 2008 Jan 10; 26(2):271-8. PMID: 18182667; PMCID: PMC3930173.
    166. Sathornsumetee S, Rich JN, Reardon DA. Diagnosis and treatment of high-grade astrocytoma. Neurol Clin. 2007 Nov; 25(4):1111-39, x. PMID: 17964028.
      View in: PubMed
    167. Vredenburgh JJ, Desjardins A, Herndon JE, Marcello J, Reardon DA, Quinn JA, Rich JN, Sathornsumetee S, Gururangan S, Sampson J, Wagner M, Bailey L, Bigner DD, Friedman AH, Friedman HS. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol. 2007 Oct 20; 25(30):4722-9. PMID: 17947719.
      View in: PubMed
    168. Rich JN, Bao S. Chemotherapy and cancer stem cells. Cell Stem Cell. 2007 Oct 11; 1(4):353-5. PMID: 18371369.
      View in: PubMed
    169. Gilbertson RJ, Rich JN. Making a tumour's bed: glioblastoma stem cells and the vascular niche. Nat Rev Cancer. 2007 10; 7(10):733-6. PMID: 17882276.
      View in: PubMed
    170. McLendon RE, Turner K, Perkinson K, Rich J. Second messenger systems in human gliomas. Arch Pathol Lab Med. 2007 Oct; 131(10):1585-90. PMID: 17922598.
      View in: PubMed
    171. Rich JN. Cancer stem cells in radiation resistance. Cancer Res. 2007 Oct 01; 67(19):8980-4. PMID: 17908997.
      View in: PubMed
    172. Hjelmeland AB, Lattimore KP, Fee BE, Shi Q, Wickman S, Keir ST, Hjelmeland MD, Batt D, Bigner DD, Friedman HS, Rich JN. The combination of novel low molecular weight inhibitors of RAF (LBT613) and target of rapamycin (RAD001) decreases glioma proliferation and invasion. Mol Cancer Ther. 2007 Sep; 6(9):2449-57. PMID: 17766837.
      View in: PubMed
    173. Sathornsumetee S, Reardon DA, Desjardins A, Quinn JA, Vredenburgh JJ, Rich JN. Molecularly targeted therapy for malignant glioma. Cancer. 2007 Jul 01; 110(1):13-24. PMID: 17520692.
      View in: PubMed
    174. Shi Q, Hjelmeland AB, Keir ST, Song L, Wickman S, Jackson D, Ohmori O, Bigner DD, Friedman HS, Rich JN. A novel low-molecular weight inhibitor of focal adhesion kinase, TAE226, inhibits glioma growth. Mol Carcinog. 2007 Jun; 46(6):488-96. PMID: 17219439.
      View in: PubMed
    175. Vredenburgh JJ, Desjardins A, Herndon JE, Dowell JM, Reardon DA, Quinn JA, Rich JN, Sathornsumetee S, Gururangan S, Wagner M, Bigner DD, Friedman AH, Friedman HS. Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res. 2007 Feb 15; 13(4):1253-9. PMID: 17317837.
      View in: PubMed
    176. Desjardins A, Quinn JA, Vredenburgh JJ, Sathornsumetee S, Friedman AH, Herndon JE, McLendon RE, Provenzale JM, Rich JN, Sampson JH, Gururangan S, Dowell JM, Salvado A, Friedman HS, Reardon DA. Phase II study of imatinib mesylate and hydroxyurea for recurrent grade III malignant gliomas. J Neurooncol. 2007 May; 83(1):53-60. PMID: 17245623.
      View in: PubMed
    177. Sathornsumetee S, Rich JN. Antiangiogenic therapy in malignant glioma: promise and challenge. Curr Pharm Des. 2007; 13(35):3545-58. PMID: 18220791.
      View in: PubMed
    178. Sathornsumetee S, Vredenburgh KA, Lattimore KP, Rich JN. Malignant glioma drug discovery - targeting protein kinases. Expert Opin Drug Discov. 2007 Jan; 2(1):1-17. PMID: 23496034.
      View in: PubMed
    179. Badruddoja MA, Penne K, Desjardins A, Reardon DA, Rich JN, Quinn JA, Sathornsumetee S, Friedman AH, Bigner DD, Herndon JE, Cahill A, Friedman HS, Vredenburgh JJ. Phase II study of Cloretazine for the treatment of adults with recurrent glioblastoma multiforme. Neuro Oncol. 2007 Jan; 9(1):70-4. PMID: 17108065; PMCID: PMC1828104.
    180. Rich JN. The cancer stem cell: a new therapeutic paradigm? Expert Rev Anticancer Ther. 2006 Nov; 6(11):1531-3. PMID: 17134357.
      View in: PubMed
    181. Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB, Dewhirst MW, Bigner DD, Rich JN. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature. 2006 Dec 07; 444(7120):756-60. PMID: 17051156.
      View in: PubMed
    182. Sathornsumetee S, Rich JN. New approaches to primary brain tumor treatment. Anticancer Drugs. 2006 Oct; 17(9):1003-16. PMID: 17001172.
      View in: PubMed
    183. Sathornsumetee S, Rich JN. Vandetanib, a novel multitargeted kinase inhibitor, in cancer therapy. Drugs Today (Barc). 2006 Oct; 42(10):657-70. PMID: 17136225.
      View in: PubMed
    184. DeKroon R, Robinette JB, Hjelmeland AB, Wiggins E, Blackwell M, Mihovilovic M, Fujii M, York J, Hart J, Kontos C, Rich J, Strittmatter WJ. APOE4-VLDL inhibits the HDL-activated phosphatidylinositol 3-kinase/Akt Pathway via the phosphoinositol phosphatase SHIP2. Circ Res. 2006 Oct 13; 99(8):829-36. PMID: 16973905.
      View in: PubMed
    185. Sathornsumetee S, Hjelmeland AB, Keir ST, McLendon RE, Batt D, Ramsey T, Yusuff N, Rasheed BK, Kieran MW, Laforme A, Bigner DD, Friedman HS, Rich JN. AAL881, a novel small molecule inhibitor of RAF and vascular endothelial growth factor receptor activities, blocks the growth of malignant glioma. Cancer Res. 2006 Sep 01; 66(17):8722-30. PMID: 16951188.
      View in: PubMed
    186. Bao S, Wu Q, Sathornsumetee S, Hao Y, Li Z, Hjelmeland AB, Shi Q, McLendon RE, Bigner DD, Rich JN. Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor. Cancer Res. 2006 Aug 15; 66(16):7843-8. PMID: 16912155.
      View in: PubMed
    187. Sathornsumetee S, Rich JN. New treatment strategies for malignant gliomas. Expert Rev Anticancer Ther. 2006 Jul; 6(7):1087-104. PMID: 16831080.
      View in: PubMed
    188. McLoughlin RM, Solinga RM, Rich J, Zaleski KJ, Cocchiaro JL, Risley A, Tzianabos AO, Lee JC. CD4+ T cells and CXC chemokines modulate the pathogenesis of Staphylococcus aureus wound infections. Proc Natl Acad Sci U S A. 2006 Jul 05; 103(27):10408-10413. PMID: 16801559.
      View in: PubMed
    189. Reardon DA, Quinn JA, Akabani G, Coleman RE, Friedman AH, Friedman HS, Herndon JE, McLendon RE, Pegram CN, Provenzale JM, Dowell JM, Rich JN, Vredenburgh JJ, Desjardins A, Sampson JH, Gururangan S, Wong TZ, Badruddoja MA, Zhao XG, Bigner DD, Zalutsky MR. Novel human IgG2b/murine chimeric antitenascin monoclonal antibody construct radiolabeled with 131I and administered into the surgically created resection cavity of patients with malignant glioma: phase I trial results. J Nucl Med. 2006 Jun; 47(6):912-8. PMID: 16741299.
      View in: PubMed
    190. Reardon DA, Rich JN, Friedman HS, Bigner DD. Recent advances in the treatment of malignant astrocytoma. J Clin Oncol. 2006 Mar 10; 24(8):1253-65. PMID: 16525180.
      View in: PubMed
    191. Reardon DA, Quinn JA, Vredenburgh JJ, Gururangan S, Friedman AH, Desjardins A, Sathornsumetee S, Herndon JE, Dowell JM, McLendon RE, Provenzale JM, Sampson JH, Smith RP, Swaisland AJ, Ochs JS, Lyons P, Tourt-Uhlig S, Bigner DD, Friedman HS, Rich JN. Phase 1 trial of gefitinib plus sirolimus in adults with recurrent malignant glioma. Clin Cancer Res. 2006 Feb 01; 12(3 Pt 1):860-8. PMID: 16467100.
      View in: PubMed
    192. Reardon DA, Akabani G, Coleman RE, Friedman AH, Friedman HS, Herndon JE, McLendon RE, Pegram CN, Provenzale JM, Quinn JA, Rich JN, Vredenburgh JJ, Desjardins A, Gururangan S, Guruangan S, Badruddoja M, Dowell JM, Wong TZ, Zhao XG, Zalutsky MR, Bigner DD. Salvage radioimmunotherapy with murine iodine-131-labeled antitenascin monoclonal antibody 81C6 for patients with recurrent primary and metastatic malignant brain tumors: phase II study results. J Clin Oncol. 2006 Jan 01; 24(1):115-22. PMID: 16382120.
      View in: PubMed
    193. Reardon DA, Egorin MJ, Quinn JA, Rich JN, Rich JN, Gururangan S, Gururangan I, Vredenburgh JJ, Desjardins A, Sathornsumetee S, Provenzale JM, Herndon JE, Dowell JM, Badruddoja MA, McLendon RE, Lagattuta TF, Kicielinski KP, Dresemann G, Sampson JH, Friedman AH, Salvado AJ, Friedman HS. Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme. J Clin Oncol. 2005 Dec 20; 23(36):9359-68. PMID: 16361636.
      View in: PubMed
    194. Hjelmeland AB, Hjelmeland MD, Shi Q, Hart JL, Bigner DD, Wang XF, Kontos CD, Rich JN. Loss of phosphatase and tensin homologue increases transforming growth factor beta-mediated invasion with enhanced SMAD3 transcriptional activity. Cancer Res. 2005 Dec 15; 65(24):11276-81. PMID: 16357132.
      View in: PubMed
    195. Rich JN, Sathornsumetee S, Keir ST, Kieran MW, Laforme A, Kaipainen A, McLendon RE, Graner MW, Rasheed BK, Wang L, Reardon DA, Ryan AJ, Wheeler C, Dimery I, Bigner DD, Friedman HS. ZD6474, a novel tyrosine kinase inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor, inhibits tumor growth of multiple nervous system tumors. Clin Cancer Res. 2005 Nov 15; 11(22):8145-57. PMID: 16299247.
      View in: PubMed
    196. Quinn JA, Desjardins A, Weingart J, Brem H, Dolan ME, Delaney SM, Vredenburgh J, Rich J, Friedman AH, Reardon DA, Sampson JH, Pegg AE, Moschel RC, Birch R, McLendon RE, Provenzale JM, Gururangan S, Dancey JE, Maxwell J, Tourt-Uhlig S, Herndon JE, Bigner DD, Friedman HS. Phase I trial of temozolomide plus O6-benzylguanine for patients with recurrent or progressive malignant glioma. J Clin Oncol. 2005 Oct 01; 23(28):7178-87. PMID: 16192602.
      View in: PubMed
    197. Rich J, Lee JC. The pathogenesis of Staphylococcus aureus infection in the diabetic NOD mouse. Diabetes. 2005 Oct; 54(10):2904-10. PMID: 16186391.
      View in: PubMed
    198. Reardon DA, Quinn JA, Rich JN, Desjardins A, Vredenburgh J, Gururangan S, Sathornsumetee S, Badruddoja M, McLendon R, Provenzale J, Herndon JE, Dowell JM, Burkart JL, Newton HB, Friedman AH, Friedman HS. Phase I trial of irinotecan plus temozolomide in adults with recurrent malignant glioma. Cancer. 2005 Oct 01; 104(7):1478-86. PMID: 16088964.
      View in: PubMed
    199. Desjardins A, Rich JN, Quinn JA, Vredenburgh J, Gururangan S, Sathornsumetee S, Reardon DA, Friedman AH, Bigner DD, Friedman HS. Chemotherapy and novel therapeutic approaches in malignant glioma. Front Biosci. 2005 Sep 01; 10:2645-68. PMID: 15970525.
      View in: PubMed
    200. Rich JN, Hans C, Jones B, Iversen ES, McLendon RE, Rasheed BK, Dobra A, Dressman HK, Bigner DD, Nevins JR, West M. Gene expression profiling and genetic markers in glioblastoma survival. Cancer Res. 2005 May 15; 65(10):4051-8. PMID: 15899794.
      View in: PubMed
    201. Dean DE, Tatarek NE, Rich J, Brogdon BG, Powers RH. Human identification from the ankle with pre- and postsurgical radiographs. J Clin Forensic Med. 2005 Feb; 12(1):5-9. PMID: 15763682.
      View in: PubMed
    202. Reardon DA, Quinn JA, Vredenburgh J, Rich JN, Gururangan S, Badruddoja M, Herndon JE, Dowell JM, Friedman AH, Friedman HS. Phase II trial of irinotecan plus celecoxib in adults with recurrent malignant glioma. Cancer. 2005 Jan 15; 103(2):329-38. PMID: 15558802.
      View in: PubMed
    203. Goudar RK, Shi Q, Hjelmeland MD, Keir ST, McLendon RE, Wikstrand CJ, Reese ED, Conrad CA, Traxler P, Lane HA, Reardon DA, Cavenee WK, Wang XF, Bigner DD, Friedman HS, Rich JN. Combination therapy of inhibitors of epidermal growth factor receptor/vascular endothelial growth factor receptor 2 (AEE788) and the mammalian target of rapamycin (RAD001) offers improved glioblastoma tumor growth inhibition. Mol Cancer Ther. 2005 Jan; 4(1):101-12. PMID: 15657358.
      View in: PubMed
    204. Shi Q, Bao S, Maxwell JA, Reese ED, Friedman HS, Bigner DD, Wang XF, Rich JN. Secreted protein acidic, rich in cysteine (SPARC), mediates cellular survival of gliomas through AKT activation. J Biol Chem. 2004 Dec 10; 279(50):52200-9. PMID: 15469933.
      View in: PubMed
    205. Rich JN, Rasheed BK, Yan H. EGFR mutations and sensitivity to gefitinib. N Engl J Med. 2004 Sep 16; 351(12):1260-1; author reply 1260-1. PMID: 15376352.
      View in: PubMed
    206. Hjelmeland MD, Hjelmeland AB, Sathornsumetee S, Reese ED, Herbstreith MH, Laping NJ, Friedman HS, Bigner DD, Wang XF, Rich JN. SB-431542, a small molecule transforming growth factor-beta-receptor antagonist, inhibits human glioma cell line proliferation and motility. Mol Cancer Ther. 2004 Jun; 3(6):737-45. PMID: 15210860.
      View in: PubMed
    207. Learn CA, Hartzell TL, Wikstrand CJ, Archer GE, Rich JN, Friedman AH, Friedman HS, Bigner DD, Sampson JH. Resistance to tyrosine kinase inhibition by mutant epidermal growth factor receptor variant III contributes to the neoplastic phenotype of glioblastoma multiforme. Clin Cancer Res. 2004 May 01; 10(9):3216-24. PMID: 15131063.
      View in: PubMed
    208. Rich JN, Bigner DD. Development of novel targeted therapies in the treatment of malignant glioma. Nat Rev Drug Discov. 2004 May; 3(5):430-46. PMID: 15136790.
      View in: PubMed
    209. Quinn JA, Reardon DA, Friedman AH, Rich JN, Sampson JH, Vredenburgh J, Gururangan S, Provenzale JM, Walker A, Schweitzer H, Bigner DD, Tourt-Uhlig S, Herndon JE, Affronti ML, Jackson S, Allen D, Ziegler K, Bohlin C, Lentz C, Friedman HS. Phase 1 trial of irinotecan plus BCNU in patients with progressive or recurrent malignant glioma. Neuro Oncol. 2004 Apr; 6(2):145-53. PMID: 15134629; PMCID: PMC1871988.
    210. Bao S, Ouyang G, Bai X, Huang Z, Ma C, Liu M, Shao R, Anderson RM, Rich JN, Wang XF. Periostin potently promotes metastatic growth of colon cancer by augmenting cell survival via the Akt/PKB pathway. Cancer Cell. 2004 Apr; 5(4):329-39. PMID: 15093540.
      View in: PubMed
    211. Reardon DA, Quinn JA, Rich JN, Gururangan S, Vredenburgh J, Sampson JH, Provenzale JM, Walker A, Badruddoja M, Tourt-Uhlig S, Herndon JE, Dowell JM, Affronti ML, Jackson S, Allen D, Ziegler K, Silverman S, Bohlin C, Friedman AH, Bigner DD, Friedman HS. Phase 2 trial of BCNU plus irinotecan in adults with malignant glioma. Neuro Oncol. 2004 Apr; 6(2):134-44. PMID: 15134628; PMCID: PMC1871982.
    212. Rich JN, Reardon DA, Peery T, Dowell JM, Quinn JA, Penne KL, Wikstrand CJ, Van Duyn LB, Dancey JE, McLendon RE, Kao JC, Stenzel TT, Ahmed Rasheed BK, Tourt-Uhlig SE, Herndon JE, Vredenburgh JJ, Sampson JH, Friedman AH, Bigner DD, Friedman HS. Phase II trial of gefitinib in recurrent glioblastoma. J Clin Oncol. 2004 Jan 01; 22(1):133-42. PMID: 14638850.
      View in: PubMed
    213. Sampson JH, Akabani G, Archer GE, Bigner DD, Berger MS, Friedman AH, Friedman HS, Herndon JE, Kunwar S, Marcus S, McLendon RE, Paolino A, Penne K, Provenzale J, Quinn J, Reardon DA, Rich J, Stenzel T, Tourt-Uhlig S, Wikstrand C, Wong T, Williams R, Yuan F, Zalutsky MR, Pastan I. Progress report of a Phase I study of the intracerebral microinfusion of a recombinant chimeric protein composed of transforming growth factor (TGF)-alpha and a mutated form of the Pseudomonas exotoxin termed PE-38 (TP-38) for the treatment of malignant brain tumors. J Neurooncol. 2003 Oct; 65(1):27-35. PMID: 14649883.
      View in: PubMed
    214. Rich J, Dean DE, Cheung YY. Forensic implications of the foot and ankle. J Foot Ankle Surg. 2003 Jul-Aug; 42(4):221-5. PMID: 12907933.
      View in: PubMed
    215. Gururangan S, McLaughlin C, Quinn J, Rich J, Reardon D, Halperin EC, Herndon J, Fuchs H, George T, Provenzale J, Watral M, McLendon RE, Friedman A, Friedman HS, Kurtzberg J, Vredenbergh J, Martin PL. High-dose chemotherapy with autologous stem-cell rescue in children and adults with newly diagnosed pineoblastomas. J Clin Oncol. 2003 Jun 01; 21(11):2187-91. PMID: 12775745.
      View in: PubMed
    216. Rich JN, Shi Q, Hjelmeland M, Cummings TJ, Kuan CT, Bigner DD, Counter CM, Wang XF. Bone-related genes expressed in advanced malignancies induce invasion and metastasis in a genetically defined human cancer model. J Biol Chem. 2003 May 02; 278(18):15951-7. PMID: 12590137.
      View in: PubMed
    217. Quinn JA, Reardon DA, Friedman AH, Rich JN, Sampson JH, Provenzale JM, McLendon RE, Gururangan S, Bigner DD, Herndon JE, Avgeropoulos N, Finlay J, Tourt-Uhlig S, Affronti ML, Evans B, Stafford-Fox V, Zaknoen S, Friedman HS. Phase II trial of temozolomide in patients with progressive low-grade glioma. J Clin Oncol. 2003 Feb 15; 21(4):646-51. PMID: 12586801.
      View in: PubMed
    218. Rich JN. The role of transforming growth factor-beta in primary brain tumors. Front Biosci. 2003 Jan 01; 8:e245-60. PMID: 12456378.
      View in: PubMed
    219. Rich J, Tatarek NE, Powers RH, Brogdon BG, Lewis BJ, Dean DE. Using pre- and post-surgical foot and ankle radiographs for identification. J Forensic Sci. 2002 Nov; 47(6):1319-22. PMID: 12455656.
      View in: PubMed
    220. Hamad NM, Elconin JH, Karnoub AE, Bai W, Rich JN, Abraham RT, Der CJ, Counter CM. Distinct requirements for Ras oncogenesis in human versus mouse cells. Genes Dev. 2002 Aug 15; 16(16):2045-57. PMID: 12183360; PMCID: PMC186434.
    221. Quinn JA, Pluda J, Dolan ME, Delaney S, Kaplan R, Rich JN, Friedman AH, Reardon DA, Sampson JH, Colvin OM, Haglund MM, Pegg AE, Moschel RC, McLendon RE, Provenzale JM, Gururangan S, Tourt-Uhlig S, Herndon JE, Bigner DD, Friedman HS. Phase II trial of carmustine plus O(6)-benzylguanine for patients with nitrosourea-resistant recurrent or progressive malignant glioma. J Clin Oncol. 2002 May 01; 20(9):2277-83. PMID: 11980998.
      View in: PubMed
    222. Reardon DA, Akabani G, Coleman RE, Friedman AH, Friedman HS, Herndon JE, Cokgor I, McLendon RE, Pegram CN, Provenzale JM, Quinn JA, Rich JN, Regalado LV, Sampson JH, Shafman TD, Wikstrand CJ, Wong TZ, Zhao XG, Zalutsky MR, Bigner DD. Phase II trial of murine (131)I-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas. J Clin Oncol. 2002 Mar 01; 20(5):1389-97. PMID: 11870184.
      View in: PubMed
    223. Pham HT, Rich J, Veves A. Using living skin equivalents for diabetic foot ulceration. Int J Low Extrem Wounds. 2002 Mar; 1(1):27-32. PMID: 15871949.
      View in: PubMed
    Jeremy's Networks
    Concepts
    Derived automatically from this person's publications.
    _
    Co-Authors
    People in Profiles who have published with this person.
    _
    Related Authors
    People who share related concepts with this person.
    _